ribonuclease A family member 3Genealiases: ECP · RAF1 · RNS3
Q-omics provides the consensus-scored RNASE3 profile across patient tissues and cancer cell-line models. RNASE3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNASE3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RNASE3 protein abundance shows 21,343 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight DLBC, KIRC, and GBM as cancer lineages where RNASE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE3 survival associations across molecular data types. RNASE3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE3 RNA expression–survival associations across cancer types. High RNASE3 expression shows unfavorable associations in DLBC, LGG, STAD and CHOL, but favorable associations in SKCM and UVM. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify DLBC as the clearest survival context for RNASE3 RNA expression.
This table summarizes RNASE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RNASE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE3 shows lower tumor expression in BRCA and higher tumor expression in KIRC, KIRP, THCA, LUAD and STAD. The KIRC box plot shows higher RNASE3 RNA expression in tumor versus normal tissue (log2 FC = +0.491, t-test p < 0.001).
This table shows molecular features associated with RNASE3 in patient tissues and cancer cell lines. In patient samples, RNASE3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
